Behavioral health company LifeStance Health (NASDAQ: LFST) announced better-than-expected revenue in Q3 2026, with sales up 25.3% year on year to $455.9 million. On top of that, next quarter’s revenue guidance ($456 million at the midpoint) was surprisingly good and 3.9% above what analysts were expecting. Its non-GAAP profit of $0.11 per share was 26.7% above analysts’ consensus estimates.
Is now the time to buy LFST? Find out in our full research report (it’s free for active Edge members).
LifeStance Health Group (LFST) Q3 2026 highlights:
- Revenue $455.9 million vs S&P analysts’ estimates of $431.7 million (25.3% year-on-year growth, 5.6% beat)
- Adjusted EPS $0.11 vs S&P analysts’ estimates of $0.08 (26.7% beat)
- Adjusted EBITDA $68.36 million vs analyst estimates of $55.31 million (15% margin, 23.6% beat)
- Revenue guidance $456 million at the midpoint for Q4 2026, above analyst estimates of $438.7 million
- EBITDA guidance $246 million at the midpoint for the full year, above analyst estimates of $228.3 million
- Operating margin 7.3%, up from 2% in the same quarter last year
- Sales volumes rose 10.8% year on year, in line with the same quarter last year
- Market capitalization $5.11 billion
StockStory’s take
LifeStance Health’s Q3 2026 results received a positive market response, reflecting strong momentum across its clinician network and specialty services. Management credited the outperformance to steady clinician recruitment, productivity gains, and broadened access to mental health care. CEO Dave Bourdon emphasized the company’s ability to grow its clinician base to over 8,800 while increasing visit volumes and maintaining high engagement, supported by ongoing enhancements to digital tools and workflow automation. The quarter was further distinguished by improvements in clinical outcomes, particularly for patients with treatment-resistant depression.
Looking ahead, management’s updated guidance is anchored in expectations for continued clinician growth, sustained expansion in specialty services, and investments in technology. CFO Ryan McGroarty highlighted that the upcoming rollout of a new electronic health record (EHR) system will temporarily moderate revenue growth, but is seen as a necessary step to improve clinician efficiency and patient access. Bourdon noted, “Once fully implemented, we remain confident that the new EHR will allow us better interoperability and flexibility as we further scale the business,” underscoring the company’s focus on scalable infrastructure and margin expansion.
Key insights from management’s remarks
Management attributed the quarter’s performance to strong clinician expansion, specialty service additions, and technology-driven productivity improvements, while also preparing for operational changes from the upcoming EHR transition.
- Specialty services expansion: The addition of new sites for Transcranial Magnetic Stimulation (TMS) and SPRAVATO, therapies aimed at treatment-resistant depression, fueled higher patient engagement and improved clinical outcomes. Management highlighted that 74% of SPRAVATO patients and 61% of TMS patients experienced meaningful reductions in depression severity, reinforcing future growth potential for specialty offerings.
- Clinician network growth: LifeStance added 321 clinicians in the quarter, bringing the total to nearly 8,900. Leadership cited strong recruiting and stable retention as key factors, with ongoing improvements to the clinician value proposition aimed at maintaining momentum in recruitment and engagement.
- Digital and AI-driven workflows: The company continued to invest in digital tools, artificial intelligence, and workflow automation to boost efficiency for both patients and clinicians. These enhancements contributed to improved productivity, with visits per average clinician rising year-over-year, and are expected to further support operating scale.
- EHR transition planning: Management advanced preparations for transitioning to a new EHR system, emphasizing a phased rollout to minimize disruption. The EHR upgrade is seen as a critical enabler for long-term growth, with anticipated benefits including improved interoperability, data access, and patient experience.
- Geographic and M&A activity: LifeStance expanded its footprint into Iowa via a tuck-in acquisition and opened eight new centers in the quarter. The company reiterated its preference for small, targeted acquisitions and de novo openings to drive geographic growth, maintaining a pipeline of opportunities for ongoing expansion.
Drivers of future performance
LifeStance’s outlook is shaped by continued clinician growth, specialty service expansion, and the timing of the EHR system transition, with management balancing investment in future growth against temporary operational headwinds.
- EHR system rollout impact: The phased transition to a new electronic health record platform is expected to temporarily reduce revenue growth by 1-2 percentage points in the coming year. Management views this as a short-term headwind, with long-term benefits including enhanced clinician efficiency, better patient access, and streamlined referral pathways.
- Continued specialty service growth: Management anticipates that specialty services like TMS and SPRAVATO will continue to grow at a rate above the company’s core business, supported by positive outcomes data and payer engagement. These services are expected to play an increasing role in revenue and margin expansion as adoption broadens.
- Stable clinician pipeline: LifeStance expects to maintain its pace of clinician additions through a combination of strong recruitment and stable retention. The company believes that its clinician-centric value proposition and the fragmented nature of the mental health market will support ongoing network growth and service capacity.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will be closely watching (1) the pace and impact of the EHR system rollout on clinician productivity and revenue growth, (2) the continued adoption and payer acceptance of specialty services like TMS and SPRAVATO, and (3) the company’s ability to recruit and retain clinicians at scale. Progress on geographic expansion and the integration of digital tools will also be important milestones for tracking execution.
LifeStance Health Group currently trades at $13.65, down from $14.21 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
Stocks that trumped tariffs
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
